Cas:26681-88-9 divinylphenylphosphine manufacturer & supplier

Chemical Name:divinylphenylphosphine

CAS.NO:26681-88-9

Synonyms:Phenyl-divinyl-phosphin;Divinylphenylphosphin;Divinylphenylphosphine;MFCD00048142;Phenyldivinylphosphine;EINECS 247-900-1

Molecular Formula:C₁₀H₁₁P

Molecular Weight:162.16800

HS Code:2902909090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:208.4ºC at 760 mmHg ,55ºC0.05 mm Hg(lit.)

Density:0.979 g/mL at 25ºC(lit.)

Index of Refraction:n20/D 1.582(lit.)

PSA:13.59000

Exact Mass:162.06000

LogP:3.08080

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Phenyl-divinyl-phosphin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 247-900-1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 247-900-1 Use and application,Phenyldivinylphosphine technical grade,usp/ep/jp grade.

Related News: The chemical compound which is in the process of becoming an API from a raw material is called an intermediate. divinylphenylphosphine manufacturer The chemical compound which is in the process of becoming an API from a raw material is called an intermediate. divinylphenylphosphine supplier Combining its core technological advantages such as ammonia oxidation, phosgenation, and fluorination, the company actively enters the field of fine and functional chemicals, and expands its focus to include polymer additives, replacement of phenolic polymer material monomers, and coating preservatives. divinylphenylphosphine vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). divinylphenylphosphine factory Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).